229 related articles for article (PubMed ID: 18922900)
1. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
Miller JK; Shattuck DL; Ingalla EQ; Yen L; Borowsky AD; Young LJ; Cardiff RD; Carraway KL; Sweeney C
Cancer Res; 2008 Oct; 68(20):8286-94. PubMed ID: 18922900
[TBL] [Abstract][Full Text] [Related]
2. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
3. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.
Shattuck DL; Miller JK; Laederich M; Funes M; Petersen H; Carraway KL; Sweeney C
Mol Cell Biol; 2007 Mar; 27(5):1934-46. PubMed ID: 17178829
[TBL] [Abstract][Full Text] [Related]
4. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
5. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
[TBL] [Abstract][Full Text] [Related]
6. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
[TBL] [Abstract][Full Text] [Related]
7. Co-opted integrin signaling in ErbB2-induced mammary tumor progression.
Carraway KL; Sweeney C
Cancer Cell; 2006 Aug; 10(2):93-5. PubMed ID: 16904607
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
9. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss.
Lozy F; Cai-McRae X; Teplova I; Price S; Reddy A; Bhanot G; Ganesan S; Vazquez A; Karantza V
Autophagy; 2014 Apr; 10(4):662-76. PubMed ID: 24492513
[TBL] [Abstract][Full Text] [Related]
10. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
12. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.
Yamaguchi N; Oyama T; Ito E; Satoh H; Azuma S; Hayashi M; Shimizu K; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Ohwada S; Tatsuta K; Inoue J; Semba K; Watanabe S
Cancer Res; 2008 Mar; 68(6):1881-8. PubMed ID: 18339869
[TBL] [Abstract][Full Text] [Related]
13. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
14. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
Spangenberg C; Lausch EU; Trost TM; Prawitt D; May A; Keppler R; Fees SA; Reutzel D; Bell C; Schmitt S; Schiffer IB; Weber A; Brenner W; Hermes M; Sahin U; Türeci O; Koelbl H; Hengstler JG; Zabel BU
Cancer Res; 2006 Apr; 66(7):3715-25. PubMed ID: 16585198
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.
Allen-Petersen BL; Carter CJ; Ohm AM; Reyland ME
Oncogene; 2014 Mar; 33(10):1306-15. PubMed ID: 23474764
[TBL] [Abstract][Full Text] [Related]
18. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
19. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract][Full Text] [Related]
20. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
